Overview
PEG-MGF (PEGylated Mechano Growth Factor) is a chemically modified version of the MGF C-terminal E-domain peptide conjugated to polyethylene glycol (PEG) to dramatically extend its biological half-life. While unmodified MGF has a plasma half-life of approximately 5–7 minutes, PEGylation increases this to several hours, making systemic administration more practical and potentially more effective.
PEGylation is a well-established pharmaceutical strategy for extending peptide and protein half-lives. The PEG moiety increases the hydrodynamic radius of the molecule, reducing renal clearance and providing steric shielding against proteolytic degradation. Several PEGylated therapeutics are FDA-approved (e.g., PEG-interferon, PEGfilgrastim), validating the technology platform though not specifically for MGF.
The rationale for PEG-MGF development stems from the pharmacokinetic limitations of native MGF. In physiological conditions, MGF acts as a local paracrine/autocrine factor within damaged muscle tissue, where its short half-life is not a limitation because it is continuously produced at the site of action. However, when administered as an exogenous therapeutic, the rapid degradation of unmodified MGF limits its ability to reach target tissues in sufficient concentrations.
PEG-MGF remains an experimental research compound without clinical trial data. Its use is primarily in bodybuilding and athletic performance contexts, where it is obtained from grey-market sources of variable quality.
Quick facts
- Mechanism
- Extended-duration satellite cell activator via PEGylated MGF E-domain
- Primary use
- Sustained Muscle Repair & Recovery
- Evidence
- low
- FDA
- Not approved
- Route
- Intramuscular or subcutaneous injection
- Typical results
- Extended satellite cell activation over hours versus minutes for unmodified MGF in preclinical models
Chemical information
PEG-MGF (PEGylated peptide) is a anabolic compound with a molecular weight of ~5,000 g/mol. Its structural characteristics underpin its biological activity in anabolic processes and muscle development.
How PEG-MGF works
PEG-MGF retains the biological activity of native MGF's C-terminal E-domain—activating muscle satellite cells from quiescence into the cell cycle—while the PEG conjugation provides protection from enzymatic degradation and reduces renal filtration. This allows systemic administration to achieve therapeutic concentrations at muscle tissue over a sustained period rather than the minutes-long window of unmodified MGF.
The PEGylation process typically involves conjugation of a 2–5 kDa PEG chain to the N-terminus or a lysine residue of the 24-amino acid MGF E-domain peptide. This increases the effective molecular weight above the renal filtration threshold (~60 kDa for PEG molecules, due to their large hydrodynamic radius) and shields protease-sensitive sites from enzymatic cleavage. The PEG chain does not directly interact with biological targets.
Once PEG-MGF reaches muscle tissue, it is thought to activate satellite cells through the same receptor-mediated mechanism as unmodified MGF, triggering the transition from G0 quiescence into G1 and subsequent proliferation. The key advantage is duration: sustained receptor activation over hours may produce a more robust satellite cell expansion than the brief pulse of activity from unmodified MGF.
However, PEGylation may also alter the tissue distribution profile of MGF. Native MGF acts locally in a paracrine fashion, but PEG-MGF circulates systemically, potentially activating satellite cells in non-target tissues. This broader distribution could be beneficial for systemic muscle wasting conditions but raises theoretical concerns about uncontrolled proliferative signals.
- Extended half-life: PEG conjugation increases plasma persistence from minutes to hours
- Protease resistance: PEG shield prevents enzymatic degradation of the peptide backbone
- Satellite cell activation: Retains native MGF's ability to trigger stem cell proliferation
- Systemic distribution: Can reach muscle tissue throughout the body rather than local action only
- Sustained signaling: Prolonged receptor occupancy may enhance total satellite cell expansion
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Weight | ~5,000 g/mol (peptide + PEG) | PEG moiety increases hydrodynamic radius above renal filtration threshold |
| Half-life | ~Several hours | Dramatically extended from 5–7 minutes for unmodified MGF |
| Administration | Subcutaneous or intramuscular | Systemic injection is practical due to extended half-life |
| PEG Size | ~2–5 kDa | Optimal PEG size for half-life extension without eliminating bioactivity |
Dosing & administration
PEG-MGF dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for PEG-MGF is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Dramatically extended half-life compared to unmodified MGF (hours vs. minutes)
- • Practical for systemic injection rather than requiring site-specific intramuscular delivery
- • Sustained satellite cell activation for enhanced muscle repair potential
- • May benefit systemic conditions involving widespread muscle wasting
- • Established PEGylation technology with FDA-approved precedents
Serious / potential risks
- • No human clinical trial safety data exists
- • PEG antibody formation possible with repeated dosing (anti-PEG antibodies)
- • Injection site reactions including swelling and erythema
- • Theoretical risk of proliferative effects in non-target tissues
- • Grey-market product quality and purity concerns
- • Unknown long-term effects of sustained satellite cell stimulation
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Unmodified MGF | Redundant | Do not combine; PEG-MGF provides the same activity with better pharmacokinetics |
| IGF-1 LR3 | Sequential/complementary | Use PEG-MGF for satellite cell expansion, then IGF-1 LR3 for differentiation |
| Growth hormone | Synergistic | GH increases systemic IGF-1 production; PEG-MGF adds satellite cell activation |
| Anti-PEG antibody risk | Cross-reactive with other PEGylated drugs | Prior PEGylated drug exposure may reduce PEG-MGF efficacy |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
PEG-MGF is a anabolic compound with research interest in muscle growth, pegylation, recovery. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying anabolic processes and muscle development
- • Individuals interested in muscle growth under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Goldspink G, Yang SY.. The splicing of the IGF-I gene to yield different muscle growth factors. Adv Genet (2004). doi: 10.1016/S0065-2660(04)52002-3 PMID: 15474972
- [2] Mills P, Dominique JC, Lafrenière JF, et al.. A synthetic mechano growth factor E peptide enhances myogenic precursor cell transplantation success. Am J Transplant (2007). doi: 10.1111/j.1600-6143.2007.01923.x PMID: 17672841
- [3] Dluzniewska J, Sarnowska A, Beresewicz M, et al.. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec. FASEB J (2005). doi: 10.1096/fj.05-3786fje PMID: 16188962
- [4] Veronese FM, Mero A.. The impact of PEGylation on biological therapies. BioDrugs (2008). doi: 10.2165/00063030-200822050-00004 PMID: 18778113